Trial
NCT02588456
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
University of Pennsylvania
Collaborators
—
Condition
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Intervention
CART22 cells
Why stopped
This study was terminated due to lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-22